These Indian students from SRIHER won the MIT COVID-19 Challenge with their ideas for a PPE suit and at-home testing – EdexLive
stemadminStem Cell ResearchNo comments

The MIT COVID-19 challenge was conducted over the internet (Pic: Sourced) Indian students are not only helping find solutions in the country during this health crisis but also contributing and acing discussions about COVID-19 prevention and cure on global platforms. Three Indian students Aishwarya Chander, Aswathy NarasimhanandJayanthi Anbalaganof theSri Ramachandra Institute of Higher Education and Research, Chennai have won theMIT COVID-19 Challenge Beat the Pandemic, a virtual 48-hour challenge to find solutions to 10 basic issues that were presented to the Massachusetts Institute of Technology by organisations involved in tackling the viral outbreak. The challenge was held from April 3-5.

Read more
Stem Cell Therapy Market Set to Witness an Uptick during 2017 to 2025 – Science In Me
stemadminBenefits Of Stem CellsNo comments

Global Stem Cell Therapy Market: Overview Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Read more
CareDx Introduces AlloCell: Cell Therapy Surveillance – Global Banking And Finance Review
stemadminStem Cell BankingNo comments

SOUTH SAN FRANCISCO, Calif., April 14, 2020 CareDx, Inc.(Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today a biopharma research partnership for AlloCell. AlloCell is a surveillance solution for patients who have received engineered-cell transplants for allogeneic cell therapy.

Read more
Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical…
stemadminMesenchymal Stem CellsNo comments

SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) -- Predictive Biology, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), announced that on April 9th it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19). The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit.

Read more
Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects – Science In Me
stemadminMesenchymal Stem CellsNo comments

The Mesenchymal Stem Cells Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry

Read more
Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha
stemadminMesenchymal Stem CellsNo comments

Orgenesis to Acquire Tamir Biotechnology's Assets for $19 Million Orgenesis Inc. (ORGS) reported that it has signed a deal with Tamir Biotechnology Inc., under which the former will acquire the assets of the latter, including its broad spectrum antiviral platform ranpirnase. The deal is cash- and stock-based and is expected to be worth nearly $19 million.

Read more

Theme: Illdy.